<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323670</url>
  </required_header>
  <id_info>
    <org_study_id>BA110</org_study_id>
    <nct_id>NCT04323670</nct_id>
  </id_info>
  <brief_title>Master Study Investigating the Guiding Catheter Selectra 3D</brief_title>
  <official_title>BIO|MASTER.Selectra 3D Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study investigating the guiding catheter Selectra 3D&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The guiding catheter 'Selectra 3D' is a catheter that is intended to support the implantation&#xD;
      of a pacemaker lead in untypical positions in the heart like in the His- bundle area.&#xD;
&#xD;
      This study is designed as post market clinical follow-up (PMCF) study to identify and&#xD;
      evaluate residual risks associated with the use of the guiding catheter Selectra 3D that&#xD;
      remained unrevealed even after risk analysis, risk mitigation and successful conformity&#xD;
      assessment. Moreover, the study aims at providing additional PMCF data, as required by&#xD;
      regulatory authorities. Furthermore, the performance and efficacy of the Selectra 3D shall be&#xD;
      assessed. The results will be used for updating the clinical evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Guiding catheter Selectra 3D</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Selectra 3D-related SADE-free rate</measure>
    <time_frame>7 days after implantation</time_frame>
    <description>Selectra 3D-related Serious adverse device effect rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful implantation rate</measure>
    <time_frame>At the day of implantation</time_frame>
    <description>Assessment, if the pacemaker lead is positioned successfully in the intended target position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriateness of sensing and pacing of Solia S</measure>
    <time_frame>12 months</time_frame>
    <description>Investigator assessment for leads in His position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SADE-free rate of Solia S</measure>
    <time_frame>6 months</time_frame>
    <description>Safety of Solia S in His position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SADE-free rate of Solia S</measure>
    <time_frame>12 months</time_frame>
    <description>Safety of Solia S in His position</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">157</enrollment>
  <condition>Pacemaker DDD</condition>
  <arm_group>
    <arm_group_label>Selectra 3D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Guiding catheter to position the brady lead into a untypical heart position</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>&quot;Selectra 3D&quot; guiding catheter</intervention_name>
    <description>His lead measurements</description>
    <arm_group_label>Selectra 3D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Standard indication for de novo pacemaker or cardiac resynchronization implantation&#xD;
&#xD;
          -  The patient is intended for guiding catheter based implantation of a pacemaker system&#xD;
&#xD;
          -  Patient is able to understand the nature of the study and has provided written&#xD;
             informed consent&#xD;
&#xD;
          -  Patient is willing and able to perform all follow up visits at the study site&#xD;
&#xD;
          -  Patient is willing and able to use the CardioMessenger and accepts the BIOTRONIK Home&#xD;
             Monitoring® concept&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AV block with no escape rhythm or broad QRS escape rhythm&#xD;
&#xD;
          -  Standard contraindications for use of the investigational devices:&#xD;
&#xD;
          -  Existing or possible occlusion of the coronary vessels or unsuitable anatomy of the&#xD;
             coronary veins&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Mechanical tricuspid valve prosthesis or severe tricuspid valve diseases&#xD;
&#xD;
          -  Intolerance against dexamethasone acetate&#xD;
&#xD;
          -  Planned cardiac surgical procedures or interventional measures in addition to the&#xD;
             study procedure within the next 6 months&#xD;
&#xD;
          -  Expected to receive heart transplantation or ventricular assist device within 1 year&#xD;
&#xD;
          -  Patient is pregnant or breast feeding&#xD;
&#xD;
          -  Less than 18 years old&#xD;
&#xD;
          -  Participating in another interventional clinical investigation&#xD;
&#xD;
          -  Life-expectancy is less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwais Mohamed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Northern Hospital, Epping, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Frömer</last_name>
    <phone>+49 151 68901243</phone>
    <phone_ext>1243</phone_ext>
    <email>simone.froemer@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Clémenty, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

